1-4 of 4
Dirk Pleimes, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Effects of a Novel Orally Bioavailable Small Molecule (Imidazolyl Ethanamide Pentandioic Acid) on Acute Radiation Syndrome

Dirk Pleimes, MD, Vivienne Bunker, Michael Meyer, Maciej Czajkowski
Journal: Blood
Blood (2018) 132 (Supplement 1): 5089.
https://doi.org/10.1182/blood-2018-99-114490
Published: 2018
Journal Articles

Induced Myelosuppression and Recommendation for Monitoring of Absolute Neutrophil Counts in Patients Treated with Epirubicin and Cyclophosphamide in Early Breast Cancer: Results from a Phase 2a Collaborative Trial of the AGO-B and CESAR Study Groups

Dirk Pleimes, MD, Volker Möbus, Frank Mayer, Marcus Schmidt, Corinna Asang, Kathrin Flunkert, Gerd Mikus
Journal: Blood
Blood (2018) 132 (Supplement 1): 5106.
https://doi.org/10.1182/blood-2018-99-114220
Published: 2018
Journal Articles

Chemotherapy Efficacy on Human Breast Cancer Xenograft in Mice Remains Effective in Combination with Myelo001, a Novel Orally Bioavailable Small Molecule to Treat Myelosuppression

Patrik PK Brehm, MSc, Neeta Donnimath, MSc, Dirk Pleimes, MD
Journal: Blood
Blood (2016) 128 (22): 5068.
https://doi.org/10.1182/blood.V128.22.5068.5068
Published: 2016
Journal Articles

Effect of IEPA, a Novel Orally Bioavailable Small Molecule, on Chemotherapy-Induced Myelosuppression

Dirk Pleimes, MD, Susanne Flechsig, PhD, Michael Meyer, PhD
Journal: Blood
Blood (2014) 124 (21): 4355.
https://doi.org/10.1182/blood.V124.21.4355.4355
Published: 2014